![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Genentech’s Tecentriq-Avastin Combo Flops in Ovarian Cancer Trial
Genentech’s Tecentriq-Avastin Combo Flops in Ovarian Cancer Trial
July 14, 2020
Genentech announced that its cancer blockluster Tecentriq (atezolizimab) failed a phase 3 trial in combination with Avastin (bevacizumab), paclitaxel and carboplatin for treatment of ovarian cancer.
The trial evaluated the combination therapy in women with stage three or four ovarian cancer who were undergoing either pre- or post-surgery adjuvant chemotherapy.
The company said the treatment regimen did not meet its target outcome of progression-free survival.
Upcoming Events
-
21Oct